Eisai (OTCMKTS:ESALY) Cut to “Hold” at Zacks Investment Research

Eisai (OTCMKTS:ESALY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

ESALY traded down $12.50 during trading on Thursday, hitting $95.24. 325,210 shares of the stock were exchanged, compared to its average volume of 27,841. Eisai has a 1 year low of $61.95 and a 1 year high of $129.79. The stock has a 50 day moving average price of $68.92. The firm has a market capitalization of $28.25 billion, a price-to-earnings ratio of 68.52, a price-to-earnings-growth ratio of 7.36 and a beta of 0.32. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.69 and a current ratio of 2.02.

Eisai (OTCMKTS:ESALY) last announced its quarterly earnings results on Wednesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. Eisai had a return on equity of 5.99% and a net margin of 6.56%. As a group, equities analysts forecast that Eisai will post 1.42 EPS for the current year.

About Eisai

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

See Also: Recession

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.